Tharimmune (NASDAQ:THAR) Trading Down 4.1% – Time to Sell?

Tharimmune, Inc. (NASDAQ:THAR) shares traded down 4.1% during mid-day trading on Friday . The stock traded as low as $2.77 and last traded at $2.79. 340,682 shares traded hands during trading, a decline of 36% from the average session volume of 532,708 shares. The stock had previously closed at $2.91.

Wall Street Analyst Weigh In

THAR has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Tharimmune in a report on Monday, December 22nd. Wall Street Zen raised Tharimmune from a “sell” rating to a “hold” rating in a report on Sunday, October 26th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Tharimmune Stock Performance

The stock has a market cap of $101.67 million, a P/E ratio of -0.70 and a beta of 1.40. The business’s 50-day moving average price is $2.79 and its 200-day moving average price is $2.70.

Tharimmune (NASDAQ:THAR) last released its earnings results on Wednesday, November 12th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.09.

Institutional Trading of Tharimmune

A number of institutional investors have recently bought and sold shares of the stock. Drucker Wealth 3.0 LLC purchased a new stake in Tharimmune in the third quarter worth $29,000. XTX Topco Ltd purchased a new position in shares of Tharimmune during the second quarter worth approximately $25,000. Finally, Franklin Resources Inc. bought a new stake in shares of Tharimmune during the second quarter valued at approximately $88,000. 1.16% of the stock is currently owned by institutional investors.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc for the development of proprietary targeted biologics; and Washington University in St.